APLS
Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
$40.95
+0.00% today
Updated 2026-04-30
Market cap
$5.24B
P/E ratio
227.50
P/S ratio
5.22x
EPS (TTM)
$0.18
Dividend yield
—
52W range
$16 – $41
Volume
5.5M
Apellis Pharmaceuticals Inc (APLS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
2.23%
Operating margin
-25.60%
ROE
7.48%
ROA
3.53%
Debt/equity
1.18x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | — | $-3.96M | — | — | — |
| 2014 | $0.00 | $-10.79M | — | — | — |
| 2015 | $0.00 | $-46.52M | — | — | — |
| 2016 | $0.00 | $-27.12M | — | — | — |
| 2017 | $0.00 | $-51.01M | — | — | — |
| 2018 | $0.00 | $-127.50M | — | — | — |
| 2019 | $0.00 | $-304.71M | — | — | — |
| 2020 | $250.65M | $-344.87M | 90.01% | -85.27% | -137.59% |
| 2021 | $66.56M | $-746.35M | 92.19% | -805.67% | -1,121.27% |
| 2022 | $75.42M | $-652.17M | 92.53% | -788.38% | -864.70% |
| 2023 | $396.59M | $-528.63M | 85.25% | -130.39% | -133.29% |
| 2024 | $781.37M | $-197.88M | 84.93% | -21.11% | -25.32% |
| 2025 | $1.00B | $22.39M | 89.81% | 5.52% | 2.23% |